ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 024,70
0,40%
Dow Jones
38 686,32
1,51%
DAX
18 636,29
0,83%
Brent Oil
81,245
0,54%
Bitcoin
69 055,28
1,93%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. FS Development Corporation II (FSII)

  7. FS Development Corporation II (FSII) Actualités

FSII

FS Development Corporati... (FSII)

FS Development Corporation II
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:FSII
DateHeureSourceTitreSymboleSociété
05/06/202322h03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FSIIFS Development Corporation II
02/06/202322h14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FSIIFS Development Corporation II
05/05/202322h06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:FSIIFS Development Corporation II
21/04/202322h28Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:FSIIFS Development Corporation II
20/04/202313h54Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:FSIIFS Development Corporation II
20/04/202313h50Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:FSIIFS Development Corporation II
14/03/202321h07Edgar (US Regulatory)Annual Report (10-k)NASDAQ:FSIIFS Development Corporation II
14/02/202323h07Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:FSIIFS Development Corporation II
23/01/202322h23Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:FSIIFS Development Corporation II
23/01/202312h03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:FSIIFS Development Corporation II
18/01/202322h08Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:FSIIFS Development Corporation II
16/09/202222h05Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:FSIIFS Development Corporation II
26/04/202212h16Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:FSIIFS Development Corporation II
07/02/202222h02Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:FSIIFS Development Corporation II
28/01/202222h46Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:FSIIFS Development Corporation II
21/01/202222h29Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:FSIIFS Development Corporation II
30/12/202122h31Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:FSIIFS Development Corporation II
27/12/202113h00GlobeNewswire Inc.Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19NASDAQ:FSIIFS Development Corporation II
23/12/202119h12Edgar (US Regulatory)Amended Securities Registration (section 12(b)) (8-a12b/a)NASDAQ:FSIIFS Development Corporation II
23/12/202117h16Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:FSIIFS Development Corporation II
21/12/202113h00Business WireFSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 InfectionsNASDAQ:FSIIFS Development Corporation II
01/12/202117h38Business WireFS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021NASDAQ:FSIIFS Development Corporation II
23/11/202122h53Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:FSIIFS Development Corporation II
23/11/202122h38Edgar (US Regulatory)Amended Quarterly Report (10-q/a)NASDAQ:FSIIFS Development Corporation II
26/08/202114h00GlobeNewswire Inc.Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 InfectionsNASDAQ:FSIIFS Development Corporation II
05/08/202113h00GlobeNewswire Inc.Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of DirectorsNASDAQ:FSIIFS Development Corporation II
29/06/202112h00Business WirePardes Biosciences & FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Adv...NASDAQ:FSIIFS Development Corporation II
17/02/202103h36Business WireFS Development Corp. II, Sponsored by Foresite Capital, Announces Pricing of Upsized $175 Million Initial Public OfferingNASDAQ:FSIIFS Development Corporation II
11/10/201222h54Edgar (US Regulatory)Current report filing (8-K)NASDAQ:FSIIFS Development Corporation II
11/10/201222h49Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (SC 14D9/A)NASDAQ:FSIIFS Development Corporation II
 Showing the most relevant articles for your search:NASDAQ:FSII

Dernières Valeurs Consultées

NASDAQ
SUNS
SLR Senior Investment
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés